Trial
NCT03904251
CPX-351 and Gemtuzumab Ozogamicin in Treating Patients With Relapsed Acute Myeloid Leukemia
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Jonsson Comprehensive Cancer Center
Collaborators
Pfizer; Jazz Pharmaceuticals; University of California, Los Angeles
Condition
Acute Myelogenous Leukemia
Intervention
Gemtuzumab Ozogamicin
Why stopped
slow accrual
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-11-18